

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PM&S FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

275300

SEI 9627 U

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Takeshi NAKAMURA

Div. of Appln. No.: 09/054,492

Filing Date: April 3, 1998

Date: December 15, 2000

Page

1

of

2

Examiner: E. Whisenant

Group Art Unit: 7655

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
U	AR 5,247,070	09/1993	Yamada et al.	530	351	
U	BR 5,798,257	08/1998	Zain et al.	435	252.3	
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
U	IR 94/09135	04/1994	WO	Beach et al.				
U	JR PCT96/02905	10/1996	JAPAN					
	KR							
	LR							
	MR							
	NR							
	OR							
	PR							
	QR							
	RR							

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

U	SR	Nakamura T. et al. "Cyclin I: A New Cyclin Encoded by a Gene Isolated from Human Brain" Exp. Cell. Res. (1995, Dec.) Vol. 221, No. 2, pgs. 534-542			
U	TR	Robert P.F. et al. "A Novel Cyclin Associates with M015/CDK7 to Form the CDK-Activating Kinase" Cell (1994) vol. 78, pgs. 713-724			
U	UR	Jonathon P. et al. "Isolation of a Human Cyclin cDNA: Evidence for Cyclin mRNA and Protein Regulation in the Cell Cycle and for Interaction with p34 ^{cdc2} Cell (1989), Vol. 58, pgs. 833-846			
U	VR	Tony Hunter et al., "Cyclins and Cancer", The Salk Institute, Cell, Vol. 66, pgs. 1071-1074, September 20, 1991			
U	WR	John Lew et al., "Neuronal cdc2-like Kinase", TIBS 20, REVIEWS, Elsevier Science Ltd., pgs. 33-37, January 1995			
U	XR	Tony Hunter et al., "Cyclins and Cancer II: Cyclin D and CDK Inhibitors Come of Age", The Salk Institute, Cell, Vol. 79, pgs. 573-582, November 18, 1994			

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PM&S FORM PAT-1449)
 Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

275300

SEI 96-2150

Applicant: Takeshi NAKAMURA

Div. of Appln. No.: 09/054,492

Filing Date: April 3, 1998

Examiner: E. Whisenant

Group Art Unit: 1655

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: December 15, 2000

Page

2

of

2

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
							Enclosed	No	Enclose	No
	IR									
	JR									
	KR									
	LR									
	MR									
	NR									
	OR									
	PR									
	QR									
	RR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

cy	SR	Tamura et al., "Cyclin G: A New Mammalian Cyclin with Homology to Fission Yeast Cig1", Research Institute for Microbial Diseases, Oncogene (1993), 8, pgs. 2113-2118			
cy	TR	Hiroshi Matsushime, "Interaction Between Cyclins and cdks", Experimental Medicine, Vol. 13, No. 6 (special number) 1995, pgs. 1-2			
cy	UR	Masahiko Ohtsuki, "Signal Transfer Factor in Focus (Intranuclear Factor Highlight 10)", Experimental medicine, Vol. 12, No. 16, (November) 1994, pgs. 1-2			
cy	VR	Daniel J. Lew et al., "Isolation of Three Novel Human Cyclins by Rescue of G1 Cyclin (Cln) Function in Yeast", The Scripps Research Institute, Cell, Vol. 66, pgs. 1197-1206, September 20, 1991			
	WR				
	XR				

Examiner

Date Considered: 2-18-00

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.